XML 93 R79.htm IDEA: XBRL DOCUMENT
v3.25.1

SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2025 | Mar. 31, 2024
Segment Reporting Information [Line Items] |  |
Net sales | $ 2,625 | $ 2,490
United States |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,490 | 1,348
International |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,135 | 1,142
Operating Segments | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 1,262 | 1,229
Operating Segments | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 704 | 667
Operating Segments | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 581 | 578
Operating Segments | United States | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 729 | 673
Operating Segments | United States | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 518 | 473
Operating Segments | United States | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 195 | 191
Operating Segments | International | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 533 | 556
Operating Segments | International | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 186 | 194
Operating Segments | International | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 386 | 387
Operating Segments | Infusion Therapies and Technologies | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 994 | 966
Operating Segments | Infusion Therapies and Technologies | United States | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 584 | 526
Operating Segments | Infusion Therapies and Technologies | International | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 410 | 440
Operating Segments | Advanced Surgery | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 268 | 263
Operating Segments | Advanced Surgery | United States | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 145 | 147
Operating Segments | Advanced Surgery | International | Medical Products & Therapies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 123 | 116
Operating Segments | Care and Connectivity Solutions | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 427 | 402
Operating Segments | Care and Connectivity Solutions | United States | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 316 | 278
Operating Segments | Care and Connectivity Solutions | International | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 111 | 124
Operating Segments | Front Line Care | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 277 | 265
Operating Segments | Front Line Care | United States | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 202 | 195
Operating Segments | Front Line Care | International | Healthcare Systems & Technologies |  |
Segment Reporting Information [Line Items] |  |
Net sales | 75 | 70
Operating Segments | Injectables and Anesthesia | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 335 | 328
Operating Segments | Injectables and Anesthesia | United States | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 195 | 191
Operating Segments | Injectables and Anesthesia | International | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 140 | 137
Operating Segments | Drug Compounding | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 246 | 250
Operating Segments | Drug Compounding | United States | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 0 | 0
Operating Segments | Drug Compounding | International | Pharmaceuticals |  |
Segment Reporting Information [Line Items] |  |
Net sales | 246 | 250
Other |  |
Segment Reporting Information [Line Items] |  |
Net sales | 78 | 16
Other | United States |  |
Segment Reporting Information [Line Items] |  |
Net sales | 48 | 11
Other | International |  |
Segment Reporting Information [Line Items] |  |
Net sales | $ 30 | $ 5

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_MedicalProductsAndTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_HealthcareSystemsAndTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bax_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_InfusionTherapiesAndTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AdvancedSurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_CareAndConnectivitySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_FrontLineCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_InjectablesAndAnesthesiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_PharmaceuticalCompoundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |